Skip to content
Screener

NeoGenomics NEO Medicare and other government — NET REVENUE

Other product segments

Client direct billing
$137.96M+5.2%
Commercial insurance
$36.27M+26.1%
Self-pay
$0-100%

Similar metrics at other companies

Surgery Partners, Inc. logo
SGRYGovernment — Revenue
$380.6M+10.3%
AAR Corp logo
AIRGovernment Programs — Revenue (Gross)
$102.3M+3.7%
Amneal Pharmaceuticals, Inc. logo
AMRXGovernment label — Net revenue
$50.21M+10.5%
Anadarko Petroleum Corporation logo
APCOther Revenues Net — Revenue (Gross)
$20.29M+33.2%
Globalstar logo
GSATGovernment and other services — Total Revenue
$1.05M+19.8%
Tutor Perini logo
TPCGovernment — Revenue
$62.95M-29.4%

Other financials

Income statement

See full
Revenue$201.7M+11.2%
Gross profit$91.9M+18.9%
Operating income-$9.8M+79.5%
Net income$2.2M+105%
EPS (diluted)$0.02+106%

Balance sheet

See full
Cash & equivalents$145.5M-5.9%
Total debt$448.4M+534%
Total equity$785.7M-8.0%
Total assets$1.4B-3.0%

Cash flow

See full
Operating cash flow$20.0M-1.8%
CapEx$8.2M+30.0%
Free cash flow-$13.1M+56.0%

Valuation

See full
Market cap$2B+182%
Enterprise value$2.3B+268%
P/S2.6×+1.6×

Profitability

See full
Gross margin43.9%0.0pp
Operating margin-8.9%-2.8pp
Net margin-6.8%-2.4pp
FCF margin-4.9%

Returns & leverage

See full
Return on equity-6.3%-2.0pp
Debt / equity0.6×+0.5×
Current ratio3.6×-0.3×

Where this comes from

Reported directly by NeoGenomics in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax.

The source filing: NeoGenomics’s 10-Q, filed July 28, 2026.

Filed
Jul 28, 2026, 4:09 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001077183-26-000059
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Client direct billing$137,956$131,157$269,545$253,195
Commercial insurance36,27328,76667,21153,623
Medicare and other government27,42721,38751,57242,488
Self-pay2059
Total net revenue$201,656$181,330$388,328$349,365

Item 1. Financial Statements (unaudited)

FAQ

What is NeoGenomics's medicare and other government — NET REVENUE?
NeoGenomics (NEO) reported medicare and other government — NET REVENUE of $27.43M in Q2 2026.
How has NeoGenomics's medicare and other government — NET REVENUE changed year-over-year?
NeoGenomics's medicare and other government — NET REVENUE increased by 28.2% year-over-year, from $21.39M to $27.43M.
What is the long-term trend for NeoGenomics's medicare and other government — NET REVENUE?
Over 4 years (2021 to 2025), NeoGenomics's medicare and other government — NET REVENUE has grown at a 6.0% compound annual growth rate (CAGR), from $72.01M to $90.87M.
What does medicare and other government — NET REVENUE mean?
This metric represents the total net revenue generated from diagnostic testing services reimbursed by Medicare and other government-sponsored healthcare programs. It reflects the company's ability to capture market share within public healthcare systems and serves as a key indicator of regulatory and reimbursement stability for clinical laboratory services.

Ask your AI about NeoGenomics's medicare and other government — net revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude